Results 11 to 20 of about 3,447,726 (212)

Impact of a digital manual for guidance on malignant hyperthermia: patient education

open access: yesOrphanet Journal of Rare Diseases, 2022
Background Malignant hyperthermia (MH) is a rare, hereditary disease with a hypermetabolic response to volatile anesthetics/succinylcholine. Susceptible patients face difficulties due to a lack of knowledge about MH.
Gislene Rodrigues   +4 more
doaj   +1 more source

Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. [PDF]

open access: yes, 2017
Malignant mesothelioma is a rare cancer that arises from the mesothelial cells that line the pleural cavity and less commonly from the peritoneal lining of the abdomen and pelvis.
Bastian, Boris C   +10 more
core   +2 more sources

Bibliometric Analysis of Chimeric Antigen Receptor-Based Immunotherapy in Cancers From 2001 to 2021

open access: yesFrontiers in Immunology, 2022
BackgroundChimeric antigen receptor (CAR)-based immunotherapy has shown great potential for the treatment of both hematopoietic malignancies and solid tumors.
Zhanpeng Ou   +16 more
doaj   +1 more source

Dual time-point FDG PET/CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area [PDF]

open access: yes, 2010
Objective. Fluorodeoxyglucose (FDG)-positron emission tomography (PET) is an accurate non-invasive imaging test for differentiating benign from malignant solitary pulmonary nodules (SPNs).
Maes, Alex   +4 more
core   +3 more sources

Malignant Mesothelioma [PDF]

open access: yesJournal of the Royal Society of Medicine, 1989
Mesothelioma is a malignant tumour of the pleura or peritoneum caused by asbestos. It is increasing in frequency and the prognosis remains grim, with average survival around 1 year.Medical literature and personal experience.Amphibole fibres are far more potent than chrysotile in causing mesothelioma.A minority view suggests that mesotheliomas in those ...
openaire   +4 more sources

Comparison of comfort and complications of Implantable Venous Access Port (IVAP) with ultrasound guided Internal Jugular Vein (IJV) and Axillary Vein/Subclavian Vein (AxV/SCV) puncture in breast cancer patients: a randomized controlled study

open access: yesBMC Cancer, 2022
Background Axillary vein/subclavian vein (AxV/SCV) and Internal jugular vein (IJV) are commonly used for implantable venous access port (IVAP) implantation in breast cancer patients for chemotherapy.
Yan Bo Chen   +8 more
doaj   +1 more source

Solvent exposure and malignant lymphoma : a population-based case-control study in Germany [PDF]

open access: yes, 2007
Aims: To analyze the relationship between exposure to chlorinated and aromatic organic solvents and malignant lymphoma in a multi-centre, population-based case-control study.
Baris   +52 more
core   +2 more sources

HE4 in the differential diagnosis of ovarian masses [PDF]

open access: yes, 2015
Ovarian masses, a common finding among pre- and post-menopausal women, can be benign or malignant. Ovarian cancer is the leading cause of death from gynecologic malignancy among women living in industrialized countries.
ANASTASI, Emanuela   +5 more
core   +1 more source

Maxillary metastasis from carcinoma lung: An unusual presentation

open access: yesAsian Journal of Oncology, 2017
Lung cancer is one of the most common cancers in the world affecting both men and woman. Common site of metastasis includes liver, adrenals, bone, and brain. Metastasis to the maxilla is very rare with only a few cases being reported so far.
Niharika Bisht   +5 more
doaj   +1 more source

CO2 lasers in the management of potentially malignant and malignant oral disorders [PDF]

open access: yes, 2012
The CO2 laser was invented in 1963 by Kumar Patel. Since the early 1970s, CO2 laser has proved to be an effective method of treatment for patients with several types of oral lesions, including early squamous cell carcinoma.
Hamdoon, Z, Hopper, C, Jerjes, W
core   +1 more source

Home - About - Disclaimer - Privacy